Medivir is a company that researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. Its product portfolio includes Remetinostat for use in the treatment of cutaneous T-cell lymphoma, Birinapant in combination with Keytruda for treating solid tumors, and MIV-711 for the treatment of osteoarthritis, as well as MIV-818, a preclinical-stage nucleoside pro-drug for treating patients with advanced liver cancers. The company also offers drugs for the treatment of labial herpes and the hepatitis C virus.